Similar Cytokine Profiles in Response to Infection with Respiratory Syncytial Virus Type A and Type B in the Upper Respiratory Tract in Infants

Intervirology ◽  
2008 ◽  
Vol 51 (2) ◽  
pp. 112-115 ◽  
Author(s):  
Jesus F. Bermejo-Martin ◽  
Alberto Tenorio ◽  
Raul Ortiz de Lejarazu ◽  
Jose M. Eiros ◽  
Vanesa Matías ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Virus Type ◽  
Type A ◽  
Upper Respiratory Tract ◽  
Type B ◽  
Cytokine Profiles ◽  
Upper Respiratory ◽  
Syncytial Virus

Respiratory viruses

2011 ◽  
pp. 208-211
Author(s):  
Dr Mark Harrison
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Common Cold ◽  
Respiratory Viruses ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
The Common ◽  
Upper Respiratory ◽  
Syncytial Virus ◽  
Tract Infections

15.1 Rhinovirus, 209 15.2 Influenza, 210 15.3 Parainfluenza, 211 15.4 Respiratory syncytial virus (RSV), 211 • There are more than 100 different serotypes of rhinovirus. • Rhinovirus is chiefly limited to upper respiratory tract infections and is the major cause of the common cold....

scholarly journals Prevalence of upper respiratory tract infections at a tertiary care hospital in the city of São Paulo

2010 ◽  
Vol 8 (2) ◽  
pp. 197-199 ◽  
Author(s):  
Amilton Mouro ◽  
Luci Black Tabacow Hidal ◽  
Marines Dalla Valle Martino ◽  
Jacyr Pasternark
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Sao Paulo ◽  
Care Hospital ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Syncytial Virus ◽  
The City

ABSTRACT Objective: To evaluate the prevalence of pathogens in the upper respiratory tract according to age at a tertiary care hospital in the city of São Paulo. Methods: A total of 6,144 biological material tests from upper respiratory airways were analyzed: 740 bacterial cultures, 726 virus screenings and 4,678 rapid tests for S. pyogenes. Results: The most frequently found etiological agent was respiratory syncytial virus (29.6%; 215/726). The main agents detected per age groups were: respiratory syncytial virus (25.34%; 184/726) in patients aged 28 days-3 years; S. pyogenes (9.5%; 70/740) in 3-12 year-old children; influenza virus (8.8%; 64/726) in adults (18-59 years). Conclusions: The etiologic agents of upper respiratory infections vary according to age and imply diverse clinical and therapeutic management.

scholarly journals Acute upper respiratory tract viral illness and influenza immunization in homes for the elderly

1990 ◽  
Vol 105 (3) ◽  
pp. 609-618 ◽  
Author(s):  
K. G. Nicholson ◽  
D. J. Baker ◽  
A. Farquhar ◽  
D. Hurd ◽  
J. Kent ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
The Elderly ◽  
Upper Respiratory Tract ◽  
Medical Conditions ◽  
Influenza Immunization ◽  
Immunization Rates ◽  
Homes For The Elderly ◽  
Upper Respiratory ◽  
Syncytial Virus

SUMMARYOccupants of 482 long-stay and 33 short-stay beds in 11 Leicester City Council homes for the elderly were studied during a 30-week period from September 1988 to March 1989 to determine the incidence, aetiology, morbidity, and mortality of acute upper respiratory tract viral infections and the use of influenza vaccine.Influenza immunization rates by home ranged from 15·4 to 90% (mean 45%). There were no differences in the distribution of medical conditions by home. The highest immunization rates were seen in people with chest disease (77%), heart disease (60%), diabetes (56%), and those with three medical conditions (75%). There was an average of 0·7 upper respiratory episodes per bed per annum with a mortality of 3·4% (6/179). Half of all episodes were seen by a general medical practitioner and 81 of 90 (90%) referrals were prescribed antibiotics costing approximately £7.50 per patient. Lower respiratory tract complications developed during 45 (25%) of 179 episodes including 3 of 12 coronavirus infections, 3 of 9 respiratory syncytial virus infections, 2 of 4 adenovirus infections, 1 of 11 rhinovirus infections, but none of 5 influenza infections. Respiratory infections were caused mostly by pathogens other than influenza virus during the influenza period documented nationally. This highlights the role of coronaviruses, respiratory syncytial virus, and unidentified agents in the elderly, and questions the assumptions made in American estimates on the impact of influenza and the value of influenza vaccines.

Serious Respiratory Tract Disease Caused by Respiratory Syncytial Virus: Prospects for Improved Therapy and Effective Immunization

PEDIATRICS ◽  
1992 ◽  
Vol 90 (1) ◽  
pp. 137-143
Author(s):  
Robert M. Chanock ◽  
Robert H. Parrott ◽  
Mark Connors ◽  
Peter L. Collins ◽  
Brian R. Murphy
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Durable Resistance ◽  
Secretory Iga ◽  
Upper Respiratory Tract ◽  
Viral Pathogen ◽  
Rsv Infection ◽  
Upper Respiratory ◽  
Syncytial Virus

On this felicitous occasion we honor Dr Saul Krugman for his many contributions to the study and control of a wide variety of important pediatric viral diseases. In preparing our remarks we found it difficult to identify a major pediatric viral pathogen upon which Saul had not left his mark. One of the few that escaped, for reasons unknown, is respiratory syncytial virus (RSV). Since RSV is the major pediatric respiratory tract viral pathogen, we thought this agent might pique his interest. Those of us studying RSV need all the help we can receive from biomedical scientists of Saul's caliber. What follows is a summary of current efforts to develop improved therapy and effective immunoprophylaxis for this elusive respiratory tract viral pathogen. IMMUNITY TO RSV DISEASE The mechanisms by which the immune system protects the respiratory tract against RSV infection and disease are not completely understood. However, it is clear that infection (or reinfection) induces resistance in the upper respiratory tract that is neither complete nor long lasting.1,2 The situation is some-what more favorable in the lower respiratory tract, where infection (or reinfection) induces more substantial and more durable resistance to disease. As a consequence, cumulative immunity from multiple reinfections protects older children and adults against the more serious forms of disease involving the lower respiratory tract such as bronchiolitis and pneumonia. Resistance to RSV infection in the upper respiratory tract appears to be mediated primarily by local secretory IgA antibodies, which explains the transitory nature of immunity in this region.3

scholarly journals Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees

1999 ◽  
Vol 73 (4) ◽  
pp. 3438-3442 ◽  
Author(s):  
Stephen S. Whitehead ◽  
Alexander Bukreyev ◽  
Michael N. Teng ◽  
Cai-Yen Firestone ◽  
Marisa St. Claire ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Recombinant Virus ◽  
Lower Respiratory Tract ◽  
Vaccine Candidate ◽  
Upper Respiratory Tract ◽  
Wild Type ◽  
Vaccine Candidates ◽  
Upper Respiratory ◽  
Syncytial Virus

ABSTRACT The NS2 and SH genes of respiratory syncytial virus (RSV) have been separately deleted from a recombinant wild-type RSV strain, A2 (M. N. Teng and P. L. Collins, J. Virol. 73:466–473, 1998; A. Bukreyev et al., J. Virol. 71:8973–8982, 1997; and this study). The resulting viruses, designated rA2ΔNS2 and rA2ΔSH, were administered to chimpanzees to evaluate their levels of attenuation and immunogenicity. Recombinant virus rA2ΔNS2 replicated to moderate levels in the upper respiratory tract, was highly attenuated in the lower respiratory tract, and induced significant resistance to challenge with wild-type RSV. The replication of rA2ΔSH virus was only moderately reduced in the lower, but not the upper, respiratory tract. However, chimpanzees infected with either virus developed significantly less rhinorrhea than those infected with wild-type RSV. These findings demonstrate that a recombinant RSV mutant lacking either the NS2 or SH gene is attenuated and indicate that these deletions may be useful as attenuating mutations in new, live recombinant RSV vaccine candidates for both pediatric and elderly populations. The ΔSH mutation was incorporated into a recombinant form of thecpts248/404 vaccine candidate, was evaluated for safety in seronegative chimpanzees, and can now be evaluated as a vaccine for humans.

Sign in / Sign up

Export Citation Format

Share Document